Cancer research
Gain a more complete understanding of cancer biology
Cancer research solutions
In order to fulfill the promise of cancer precision medicine, a better understanding of cancer’s complex biology is needed. PacBio’s highly accurate long reads allow you to uncover novel isoforms, fusions, and structural variants with unmatched accuracy.
RNA ISOFORM + FUSION DISCOVERY
Cancer exhibits widespread RNA dysregulation. The Iso-Seq method uncovers the full repertoire of alternative splicing and fusion events.
STRUCTURAL VARIANT DETECTION
Structural variants (genomic differences ≥50 base pairs) are one of the main drivers of cancer. Most structural variants are too large to reliably discover with short-read DNA sequencing.
WHOLE GENOME SEQUENCING OF GERMLINE VARIANTS
Best-in-class variant calling for all variant types including single nucleotide variants (SNV), indels, and copy number variants (CNVs).
WEBINAR
The RNA Isoform Landscape of Cancer
WEDNESDAY, JULY 20, 2022
9:00 am PDT | 11:00 am CDT | 12:00 pm EDT | 5:00 pm BST
Learn how PacBio’s accurate long-read RNA sequencing provides true discovery power of cancer-related RNA isoforms and allows for the understanding of molecular mechanisms underlying cancer biology
Cancer research in action
Publication
A comprehensive long-read isoform analysis platform for breast cancer
Long-read RNA sequencing identifies novel biomarkers and drug targets in breast cancer.


Complex oncogene amplifications revealed
A detailed map of structural variations in breast cancer.
AACR 2022
Featuring the work of the best minds in cancer research from institutions all over the world…

Delivering new insights into cancer research
Meredith Ashby highlights the value of SMRT sequencing for deeper understanding of tumors at the genomic and transcriptomic level.
Explore
Did you know we have a comprehensive library of articles, reports, papers, and videos related to cancer research?
Shaping the future
Long reads reveal differences in drug response
Science
Research reveals that breast cancer patients with double mutations in cis have significantly increased P13K activity and downstream pathway activation and show enhanced sensitivity to PIK3CA targeted therapy.
Sequel II Systems
The Sequel II system can generate longer reads with greater accuracy and throughput, at a significantly lower cost.